PTAB Applies State Sovereign Immunity in IPR

Feb 2, 2017

Reading Time : 2 min

The dispute between Covidien and UFRF arose from a breach-of-license contract between the parties concerning the ’251 patent. In a Florida state court action, UFRF alleged that Covidien breached its contract with UFRF. Covidien filed a declaratory judgment counterclaim of noninfringement. Covidien removed the case to the Northern District of Florida, where UFRF argued that it was an arm of the state of Florida and therefore entitled to state sovereign immunity protection under the 11th Amendment. The district court agreed and remanded the action back to state court.

UFRF argued that the same immunity applied and required dismissal of Covidien’s petitions. The PTAB agreed, relying on the Supreme Court’s opinion in Fed. Mar. Comm’n v. South Carolina State Ports Auth.1 and the Federal Circuit’s decision in Vas-Cath, Inc. v. Curators of the University of Missouri.2 Covidien argued that these decisions did not apply to inter partes reviews because patents are public rights and that 11th Amendment immunity is limited by a public-rights exception. The PTAB disagreed, stating that the case law Covidien relied on did not address the issue before the PTAB. Covidien also argued that sovereign immunity is irrelevant because inter partes reviews are not suits against the state, but instead are directed at the patent itself. The PTAB disagreed with this argument as well, observing that inter partes reviews are not directed only at the patent and that the AIA provides protection for patent owners who are harassed through the inter partes review process.

The PTAB held that inter partes reviews are adversarial and that they are similar to civil litigation in federal courts. The PTAB also noted similarities between the role of an APJ in an inter partes review and the role of an Article III judge in a civil litigation. The PTAB concluded that the similarities between the nature of an inter partes review and a civil litigation are “sufficient to implicate the immunity afforded to the States by the Eleventh Amendment.”

Next, the PTAB analyzed whetherUFRF was “an arm of the State.”UFRF argued that a district court had already held that it was an arm of the state and that the PTAB should follow this previous determination. The PTAB found thatUFRF was statutorily connected to the state of Florida as a direct-support organization, and that the University of Florida and state of Florida operated significant control overUFRF. Based on the state’s control overUFRF and the previous district court’s finding, the PTAB found thatUFRF was an arm of the state of Florida and that the 11thAmendment immunity applied. The PTAB dismissed all three Covidien petitions.

Covidien LP v. Univ. of Fla. Research Found., Inc., IPR2016-01274, IPR2016-01275, IPR2016-01276 (Jan. 25, 2017).

1 535 U.S. 743 (2002).

2 473 F.3d 1376 (Fed. Cir. 2007).

Share This Insight

Previous Entries

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

IP Newsflash

April 23, 2025

The Federal Circuit recently refused to apply collateral estoppel to claims of a patent asserted in district court litigation based on a Patent Trial and Appeal Board (PTAB) decision finding similar claims from the same patent unpatentable because the PTAB applied a lower burden of proof than what is required to invalidate claims in district court.

...

Read More

IP Newsflash

April 7, 2025

The Central District of California denied a defendant’s motion to dismiss or transfer plaintiff’s first-filed declaratory judgment action based on defendant’s later-filed patent infringement suit in Wisconsin.  Though suit was seemingly imminent when defendant advised plaintiff it might be infringing defendant’s patents, plaintiff responded by requesting a licensing agreement in lieu of litigation. The court found that plaintiff’s action was not anticipatory forum-shopping litigation because plaintiff only filed suit after defendant neglected to respond to its licensing offer.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.